New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

about

Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.The Expression of Actin-Related Protein 2/3 Complex Subunit 5 (ARPC5) Expression in Multiple Myeloma and its Prognostic Significance

P2860

Q47784917-1D349DD4-916C-45C8-8F25-F9B40BD37AC1 Q58749971-BB095664-B4EB-40A2-81D2-252A6E178A63

P2860

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

Item

http://www.wikidata.org/entity/Q38598891

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

New developments in the manage ...... yeloma - the role of ixazomib.

@en

type

Item

label

New developments in the manage ...... yeloma - the role of ixazomib.

@en

prefLabel

New developments in the manage ...... yeloma - the role of ixazomib.

@en

P1476

New developments in the manage ...... yeloma - the role of ixazomib.

@en

P2093

Claudia Paba-Prada

http://www.w3.org/2001/XMLSchema#string

Deborah Berg

http://www.w3.org/2001/XMLSchema#string

Helgi van de Velde

http://www.w3.org/2001/XMLSchema#string

Jacob P Laubach

http://www.w3.org/2001/XMLSchema#string

Neeraj Gupta

http://www.w3.org/2001/XMLSchema#string

Shaji Kumar

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib

Cancer statistics, 2015

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

P304

107-121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/JBM.S102328

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paul G Richardson

Philippe Moreau

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28860887

http://www.w3.org/2001/XMLSchema#string

P932

5573039

http://www.w3.org/2001/XMLSchema#string

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

about

P2860

P2860

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P932